{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:04:24Z","timestamp":1791198264912,"version":"4.1.0"},"reference-count":47,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2006,8,9]],"date-time":"2006-08-09T00:00:00Z","timestamp":1155081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2007,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To estimate the net cardiovascular (CV) (coronary heart disease, stroke, congestive heart failure), and gastrointestinal (GI) (peptic ulcer complications) risk\u2010benefit public health impact of the use of celecoxib compared to non\u2010selective NSAIDs in the arthritis population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We applied discrete event simulation models to data from the US National Health Surveys, CV risk\u2010prediction models from the Framingham Heart Study, and population\u2010based studies. Models took into account the multifactorial effect of risk factors, comorbidity, and competing risk of mortality. We simulated the natural history of CV and GI disease in the U.S. arthritis population over 1 year, through the individual baseline cardiovascular and gastrointestinal risk profile. This model was modified with relative risks associated with the use of each treatment. The mean number of events was estimated for each end\u2010point in each model: natural history, celecoxib, diclofenac, ibuprofen, naproxen. The number of events for celecoxib was compared with each NSAID.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The evaluation included 1% of the U.S. population with arthritis. Celecoxib, when applied to 100\u2009000 patients over 1 year, resulted in 570 (range from sensitivity analysis: 440\u2013691), 226 (124\u2013313), and 746 (612\u2013868) fewer ulcer complications than diclofenac, ibuprofen, and naproxen, respectively. There were 20 (16\u201325), 8 (4\u201312), and 27 (22\u201332) fewer deaths from ulcer complications, respectively. No increase in cardiovascular events or all cause mortality was observed for celecoxib versus the other individual NSAIDs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Results from these simulations suggest a gastrointestinal benefit for celecoxib not offset by increased cardiovascular events or mortality. The methodology used here provides a risk\u2010benefit assessment framework for evaluating the public heath impact of drugs. Copyright \u00a9 2006 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.1299","type":"journal-article","created":{"date-parts":[[2006,8,9]],"date-time":"2006-08-09T12:12:10Z","timestamp":1155125530000},"page":"366-376","source":"Crossref","is-referenced-by-count":12,"title":["Quantitative assessment of the gastrointestinal and cardiovascular risk\u2010benefit of celecoxib compared to individual NSAIDs at the population level"],"prefix":"10.1002","volume":"16","author":[{"given":"Cristina","family":"Varas\u2010Lorenzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Castellsague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Perez\u2010Gutthann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,8,9]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(00)00681-1"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.14.2093"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(00)00682-3"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.10.1247"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011233432103"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16893-1"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X43686"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.119.1_suppl.39S"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000124715.27937.78"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199717050-00001"},{"issue":"2","key":"e_1_2_1_12_2","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0022-3565(24)38195-9","article-title":"Effects of specific inhibition of cyclooxygenase\u20102 on sodium balance, hemodynamics, and vasoactive eicosanoids","volume":"289","author":"Catella\u2010Lawson F","year":"1999","journal-title":"JPET"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(01)02265-2"},{"issue":"48","key":"e_1_2_1_14_2","first-page":"9","article-title":"Merck Arcoxia at ACR: data suggest thrombotic profile similar to Vioxx","volume":"63","author":"FDC reports","year":"2001","journal-title":"Pink Sheet"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16894-3"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050493"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050330"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5223(03)00125-9"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050405"},{"key":"e_1_2_1_20_2","unstructured":"Pfizer Statement on New Information Regarding Cardiovascular Safety of Celebrex [online]. Available from URL:http:\/\/www.pfizer.com\/pfizer\/are\/investors_releases\/2004pr\/mn_2004_1217.jsp."},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/hec.770"},{"key":"e_1_2_1_22_2","unstructured":"U.S. Department of Health and Human Services Public Health Service Centers for Disease Control and Prevention National Center for Health Statistics.Plan and Operation of the Third National Health and Nutrition Examination Survey 1988\u201394. Hyattsville MD: U.S. Department of Health and Human Services;1994."},{"issue":"193","key":"e_1_2_1_23_2","article-title":"Current estimates from the National Health Interview Survey, 1994. National Center for Health Statistics","volume":"10","author":"Adams PF","year":"1995","journal-title":"Vital Health Stat"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(00)90236-9"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.22.3.312"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.25.1.40"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(93)90455-A"},{"issue":"1","key":"e_1_2_1_28_2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0002-9149(79)90250-9","article-title":"Prognosis after initial myocardial infarction: the Framingham study","volume":"44","author":"Kannel WB","year":"1979","journal-title":"Am J Cardiol"},{"issue":"3","key":"e_1_2_1_29_2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1161\/01.STR.13.3.290","article-title":"Survival and recurrence following stroke. The Framingham study","volume":"13","author":"Sacco RL","year":"1982","journal-title":"Stroke"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(86)90155-9"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-199701000-00003"},{"issue":"8","key":"e_1_2_1_32_2","first-page":"667","article-title":"Risk factors for rebleeding and fatal outcome in elderly patients with acute peptic ulcer bleeding","volume":"10","author":"Hasselgren G","year":"1998","journal-title":"Eur J Gastroen Hepatol"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-199807000-00018"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/jech.54.2.130"},{"key":"e_1_2_1_35_2","unstructured":"Death rates from 282 Selected Causes by 5\u2010Year Age Groups Race and Sex: United States 1979\u201398. National Center for Health Statistics. Data Warehouse.http:\/\/www.cdc.gov\/nchs\/datawh\/statab\/unpubd\/mortabs\/gmwk292a.htm"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2006.pto_302.x"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16299-5"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.325.7365.624"},{"key":"e_1_2_1_39_2","volume-title":"NHANES III: Weighting and Estimation Methodology: NCHS Executive Summary","author":"Mohadjer L","year":"1996"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-2456(96)00233-4"},{"key":"e_1_2_1_41_2","first-page":"S128","article-title":"Non\u2010steroidal anti\u2010inflammatory drug use: impact of risk factors for gastropathy on prescribing practices","volume":"11","author":"Moride Y","year":"2002","journal-title":"Pharmacoepidemiol Drug Safe"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.9.1265"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2003.08.025"},{"issue":"7","key":"e_1_2_1_44_2","first-page":"1648","article-title":"Patterns of drug use in rheumatoid arthritis","volume":"27","author":"B\u00e9rard A","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-#"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000054612.26458.B2"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.10.1108"},{"key":"e_1_2_1_48_2","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/01.EDE.0000034633.74133.C3","article-title":"Nonsteroidal antiinflammatory drugs as a trigger of clinical heart failure","volume":"14","author":"Garc\u00eda\u2010Rodr\u00edguez LA","year":"2003","journal-title":"Epidemiology"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1299","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.1299","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T11:09:43Z","timestamp":1736507383000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.1299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8,9]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["10.1002\/pds.1299"],"URL":"https:\/\/doi.org\/10.1002\/pds.1299","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8,9]]}}}